| Tohono O'odham Hospice Federal Route 15, Mile Post 9, Sells, AZ, 85634 | |
| (520) 383-1893 |
News Archive
Some caregivers in rural Malawi have expressed a reluctance to begin antiretroviral therapy for children living with HIV because of a belief that their "bodies were too weak for pills and their blood was 'still raw,' but that as it 'ripened' with time, HIV-related opportunistic infections would leave them," according to a study presented this week at the 1st International HIV Social Science and Humanities Conference in Durban, South Africa, PlusNews reports.
"It won't happen to me." Maybe that sentiment explains consumers' attitude toward long-term disability insurance, which pays a portion of your income if you are unable to work.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).
Cases of endocarditis - infection of the heart valves - have risen dramatically in recent years as a result of the opioid crisis. In London, Ontario 55 per cent of people who experience heart valve infections are injection drug users. They are particularly vulnerable to the disease and a third die as a result.
› Verified 1 days ago
| Name | Tohono O'odham Hospice |
|---|---|
| Location | Federal Route 15, Mile Post 9, Sells, Arizona |
| Hospice ID | 031576 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| SSA county code | 090 |
News Archive
Some caregivers in rural Malawi have expressed a reluctance to begin antiretroviral therapy for children living with HIV because of a belief that their "bodies were too weak for pills and their blood was 'still raw,' but that as it 'ripened' with time, HIV-related opportunistic infections would leave them," according to a study presented this week at the 1st International HIV Social Science and Humanities Conference in Durban, South Africa, PlusNews reports.
"It won't happen to me." Maybe that sentiment explains consumers' attitude toward long-term disability insurance, which pays a portion of your income if you are unable to work.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).
Cases of endocarditis - infection of the heart valves - have risen dramatically in recent years as a result of the opioid crisis. In London, Ontario 55 per cent of people who experience heart valve infections are injection drug users. They are particularly vulnerable to the disease and a third die as a result.
› Verified 1 days ago
| NPI Number | 1093838658 |
| Organization Name | Archie Hendricks Sr. Skilled Nursing Fascility |
| Address | Federal Route 15 Mile Post 9 Sells, Arizona, 85634 |
| Phone Number | (520)361-1800 |
News Archive
Some caregivers in rural Malawi have expressed a reluctance to begin antiretroviral therapy for children living with HIV because of a belief that their "bodies were too weak for pills and their blood was 'still raw,' but that as it 'ripened' with time, HIV-related opportunistic infections would leave them," according to a study presented this week at the 1st International HIV Social Science and Humanities Conference in Durban, South Africa, PlusNews reports.
"It won't happen to me." Maybe that sentiment explains consumers' attitude toward long-term disability insurance, which pays a portion of your income if you are unable to work.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).
Cases of endocarditis - infection of the heart valves - have risen dramatically in recent years as a result of the opioid crisis. In London, Ontario 55 per cent of people who experience heart valve infections are injection drug users. They are particularly vulnerable to the disease and a third die as a result.
› Verified 1 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
Some caregivers in rural Malawi have expressed a reluctance to begin antiretroviral therapy for children living with HIV because of a belief that their "bodies were too weak for pills and their blood was 'still raw,' but that as it 'ripened' with time, HIV-related opportunistic infections would leave them," according to a study presented this week at the 1st International HIV Social Science and Humanities Conference in Durban, South Africa, PlusNews reports.
"It won't happen to me." Maybe that sentiment explains consumers' attitude toward long-term disability insurance, which pays a portion of your income if you are unable to work.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).
Cases of endocarditis - infection of the heart valves - have risen dramatically in recent years as a result of the opioid crisis. In London, Ontario 55 per cent of people who experience heart valve infections are injection drug users. They are particularly vulnerable to the disease and a third die as a result.
› Verified 1 days ago
| Home Health Aides | 1 |
| Counselors | 1 |
| Homemakers | 1 |
| Medical Social Workers | 0.2 |
| Registered Nurses | 0.8 |
| Total Employees | 4 |
|---|
News Archive
Some caregivers in rural Malawi have expressed a reluctance to begin antiretroviral therapy for children living with HIV because of a belief that their "bodies were too weak for pills and their blood was 'still raw,' but that as it 'ripened' with time, HIV-related opportunistic infections would leave them," according to a study presented this week at the 1st International HIV Social Science and Humanities Conference in Durban, South Africa, PlusNews reports.
"It won't happen to me." Maybe that sentiment explains consumers' attitude toward long-term disability insurance, which pays a portion of your income if you are unable to work.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).
Cases of endocarditis - infection of the heart valves - have risen dramatically in recent years as a result of the opioid crisis. In London, Ontario 55 per cent of people who experience heart valve infections are injection drug users. They are particularly vulnerable to the disease and a third die as a result.
› Verified 1 days ago
| Tohono O'odham Hospice Location: Federal Route 15, Mile Post 9, Sells, Arizona, 85634 Phone: (520) 383-1893 |